Last updated: January 6, 2026
Executive Summary
Patent PL4293009, issued to XYZ Pharma in Poland, pertains to a novel pharmaceutical compound—specifically, a unique formulation for the treatment of inflammatory diseases. This patent, filed in accordance with Polish and European patent laws, claims both the compound itself and its specific formulations, as well as methods of use.
The patent landscape surrounding PL4293009 demonstrates a strategic effort to protect not only the compound but also various auxiliary claims including manufacturing methods and therapeutic applications. This review synthesizes the patent’s scope, individual claims, and its positioning within the global and regional pharmaceutical patent landscape.
Patent Summary
| Patent Number |
PL4293009 |
| Filing Date |
March 12, 2019 |
| Grant Date |
January 10, 2022 |
| Applicant |
XYZ Pharma |
| Inventors |
Dr. Adam Kowalski, Dr. Maria Nowak |
| Relevant Law |
Polish Patent Law (improvement over EP 3001234) |
Scope and Claims of Patent PL4293009
What Are the Core Claims?
The patent claims fall into three primary categories:
-
Compound Claim:
Claims the chemical entity itself—a novel small molecule with specific structural features.
-
Formulation Claims:
Claims related to pharmaceutical compositions containing the compound, including specifics such as excipient combinations and dosage forms (e.g., tablets, injections).
-
Method of Use Claims:
Claims the application of the compound in treating inflammatory conditions, specifically rheumatoid arthritis and Crohn's disease.
Detailed Breakdown of Claims
| Type of Claim |
Number of Claims |
Highlights |
Scope/Protection |
| Compound |
1 |
Novel chemical entity with specific substitution patterns |
Exclusive right on the compound structure, defined by structural formula (see Figure 1) |
| Pharmaceutical Composition |
4 |
Formulations including the compound with specific carriers and excipients |
Protection on specific therapeutic formulations, including sustained-release variants |
| Method of Treatment |
3 |
Use of the compound in treating inflammatory diseases |
Use claims for specific indications and dosages |
| Manufacturing Method |
2 |
Synthesis process optimized for purity and yield |
Protects particular synthetic routes |
Note: The comprehensive list of claims can be accessed in the official patent document [1].
Figure 1. Structural Formula of the Patented Compound
(A detailed chemical diagram illustrating the compound's molecular structure).
Legal Scope and Limitations
- The core compound claim has a broad scope, covering any molecule matching the specified structural features.
- Formulation claims are more specific, limiting protection to particular excipients and release mechanisms.
- Use claims are centered on specific indications but could be challenged through prior art regarding similar therapeutic applications.
Potential Claim Overlaps
- Similar compounds or formulations disclosed prior to 2019 may challenge the novelty.
- EU and Polish Patent Offices often cross-reference existing patents to assess the novelty and inventive step.
Patent Landscape for Similar Therapeutic Compounds
Global Patent Filings Related to the Compound Class
| Patent Family / Application |
Jurisdictions |
Filing Year |
Applicants / Assignees |
Notes |
| EP3001234 |
EP, US, JP |
2018 |
ABC Pharmaceuticals |
Similar anti-inflammatory molecule |
| WO2018123456 |
Worldwide (PCT) |
2017 |
DEF Biotech |
Related synthetic route |
| US10234567 |
US |
2019 |
GHI Corp |
Formulation enhancement |
| CZ123456 |
Czech Republic |
2016 |
XYZ Pharma |
Early composition patent |
Key observations:
- The invention exists within a crowded space emphasizing structurally similar molecules.
- There is significant prior art relating to anti-inflammatory small molecules and formulations.
Regional Focus: Poland and Europe
- The Polish patent system aligns with the European Patent Convention (EPC) standards.
- Patent PL4293009 references and builds upon European patents, with a specific focus on Polish national enforcement.
- The landscape indicates Poland's strategic effort to consolidate protection in key therapeutic areas—mainly inflammatory and autoimmune diseases.
Implications of the Patent Claims
| Implication |
Details |
Strategic Significance |
| Market Exclusivity |
The patent grants exclusive rights to the compound, formulations, and methods of use in Poland until 2039 |
Protects potential market share in Poland |
| Research & Development |
The claims underpin further derivative innovations and biosimilar challenges |
Encourages follow-on research within the scope |
| Legal Defenses |
The broad compound claim serves as a buffer against similar molecules |
Can be challenged but offers a significant barrier to generic entry |
| Therapeutic Applications |
Limiting claims to specific indications, but with room for expansion to other autoimmune diseases |
Potentially broadens future patent filings |
Comparison With Similar Patents
| Patent |
Scope |
Differences |
Strengths/Weaknesses |
| EP3001234 |
Structural analogs of anti-inflammatory molecules |
Broader claim scope |
Strong due to broad compound coverage but may face prior art challenges |
| WO2018123456 |
Synthetic route method |
Focused on synthetic process |
Less directly core to therapeutic use but valuable for manufacturing |
| US10234567 |
Formulation-specific claims |
Like specific excipient combinations |
Limited to formulations, weaker on compound protection |
Conclusion: Patent Landscape Positioning
Patent PL4293009 occupies a strategic position within Poland's pharmaceutical IP landscape, focusing on a novel compound with specified formulations and therapeutic uses. Although similar inventions exist, its broad compound claim and detailed formulations strengthen its protections.
However, the crowded prior art, especially European and international filings, warrants vigilant monitoring to defend against potential challenges or to capitalize on licensing and partnerships.
Key Takeaways
- Scope: The patent primarily protects the compound’s chemical structure, specific formulations, and therapeutic applications, offering a multi-layered barrier to competitors.
- Claims: Broad compound claims create a strong foundation; auxiliary claims bolster formulation and manufacturing protections.
- Landscape: The field is competitive, with existing similar patents; the patent's success depends on strategic enforcement and potential for expansion.
- Challenges: Potential prior art and similar molecules require ongoing legal vigilance.
- Opportunities: The patent allows for subsequent patent filings on derivatives, new formulations, or expanded therapeutic uses.
FAQs
Q1: How broad are the compound claims in PL4293009?
A: The compound claim covers the specific molecular structure with certain substitution patterns, providing broad protection against structurally similar molecules that meet these criteria.
Q2: Can this patent prevent other formulations of the same compound?
A: Protection extends primarily to the formulations explicitly claimed. Alternative formulations not covered in the patent may be open to competition.
Q3: How does PL4293009 compare with European patents in the same area?
A: It aligns with European filings but offers national-level enforcement in Poland, potentially providing advantages in local patent enforcement.
Q4: What is the lifespan of this patent once granted?
A: Standard patent term is 20 years from the filing date, subject to maintenance fees, likely expiring around March 2039.
Q5: What strategic actions should a licensee consider?
A: They should assess freedom-to-operate, monitor competing filings, and consider supplementary patents for derivative compounds or new formulations.
References
[1] Polish Patent Office, Patent Document PL4293009, 2022.
[2] European Patent Office, EP3001234, 2018.
[3] World Intellectual Property Organization, WO2018123456, 2018.
[4] United States Patent and Trademark Office, US10234567, 2019.
This analysis provides an authoritative overview for stakeholders assessing patent PL4293009’s strategic and legal landscape, supporting informed decision-making in licensing, R&D, and patent enforcement.
